Growing Number of Leprosy Cases Reported After COVID-19 Vaccination
By Zachary Stieber – originally published on The Epoch Times
All links to previous Gospa News articles have been added aftermath for relevance to the topics highlighted
A growing number of leprosy cases are being reported after COVID-19 vaccination, including two cases in the United Kingdom that researchers said may have been caused by the vaccines.
The researchers examined records from the Leprosy Clinic at the Hospital for Tropical Diseases in London. They found that of the 52 people who went to the clinic in 2021, at least 49 were vaccinated.
The study definition of a leprosy adverse event associated with a COVID-19 vaccine included developing leprosy or a leprosy reaction within 12 weeks of receiving a dose and the person having no previous history of leprosy or a leprosy reaction.
Two people met the case definition. One developed borderline tuberculoid (BT) leprosy one week after a second dose. The other experienced a reaction 56 days after a dose. Both doses were Pfizer’s BNT162b2 vaccine. Pfizer did not respond to a request for comment.
“The development of BT leprosy and a Type 1 reaction in another individual shortly after a dose of BNT162b2 vaccine may be associated with vaccine mediated T cell responses,” the researchers said.
The COVID-19 vaccines can provoke a response from white blood cells, or T cells. The cells are believed to protect against COVID-19.
T-cells can theoretically trigger Mycobacterium leprae, a bacteria that causes leprosy, leading to leprosy or a leprosy reaction, the researchers said.
Other vaccines have been shown to trigger leprosy or leprosy reactions, including tuberculosis vaccines, and some people who receive repeated COVID-19 vaccinations have been shown to have weakened immune systems.
The paper was published on Aug. 4 by PLOS Neglected Tropical Diseases.
More on Findings
The person diagnosed with leprosy is an 80-year-old man who has lived in the United Kingdom for 49 years. He suffered from symptoms including thickened nerves. The leprosy diagnosis was confirmed via skin biopsy. The man may be the first to acquire leprosy in the UK since 1954.
The man improved over time and actually received a third dose of Pfizer’s vaccine.
“Interestingly he had a third dose of BNT162b2 vaccine six months after the second dose having started anti-bacterial therapy and experienced no deterioration of his leprosy. The skin lesions and nerve thickening had resolved by the time he completed the six-month course of anti-microbial therapy. There had been no recurrence of the plaques or nerve signs after 12 months,” the researchers said.
The reaction was recorded in a 27-year-old man who had taken multidrug therapy, a drug for leprosy, in the past. He developed red plaques and thickened nerves before arriving in the UK from an unidentified country. A biopsy supported the diagnosis. He took medicine and the symptoms improved.
The link between the vaccine and the issue in the second case was strengthened by studies showing people who took the therapy three years or more years before are unlikely to experience a new reaction, the researchers said.
Of the 52 people who went to the Leprosy Clinic for diagnosis and/or treatment in 2021, all but two reported their vaccination status. Of those 50, 49 were vaccinated.
Five of the patients at the clinic were newly diagnosed with leprosy in 2021. Five others had a type one reaction. All were vaccinated, but just one of each category was determined to be possibly caused by a vaccine after being diagnosed within 12 weeks of vaccination. It was not clear when the other four were vaccinated.
The authors reported no funding or competing interests.
“Leprosy cases are not increasing due to covid-19 vaccines. Covid-19 vaccines are safe, saved many lives and were crucial to fight the pandemic,” Dr. Barbara de Barros, the study’s corresponding author, told The Epoch Times via email.
Dr. de Barros and the other UK researchers said in the paper that doctors should be aware that COVID-19 vaccination may cause leprosy but that they believe the benefits of COVID-19 vaccination “outweigh these unwanted events.”
They provided no citations for the benefits of vaccination, which have dropped dramatically as newer variants have emerged and led to more nuanced recommendations in some countries. Citations for scope of harm included a 2021 recommendation from India that people with leprosy receive a COVID-19 vaccine.
At least 14 other cases of leprosy or a leprosy reaction within 14 days of COVID-19 vaccination have been reported in the literature, including eight in India. The patients were all said to have eventually recovered, and some received additional vaccine doses.
In a paper published in 2021, Brazilian researchers reported two leprosy reactions called erythema nodosum leprosum after COVID-19 vaccination. They said that doctors “need to be made aware of the occurrence of erythema nodosum leprosum that may appear in patients that are vaccinated” and “have to look for the signals of active leprosy in these patients for a possible diagnose of a new case of leprosy, relapse, or reinfection.”
In December 2021, Singaporean researchers reported a new leprosy diagnosis following COVID-19 vaccination and said the problem was “likely unmasked by the COVID-19 vaccine.”
Also in 2021, Indonesian researchers reported a patient who suffered a reaction after COVID-19 vaccination.
In March 2022, Israeli researchers reported a reaction and said early diagnosis and treatment were important.
In a case series published in 2022, Indian researchers reported four men who experienced leprosy or a reaction within 11 days of COVID-19 vaccination. The researchers said that the “sheer versatility of clinical presentation of leprosy reactions following COVID‐19 vaccination warrants further large‐scale molecular studies.”
In another paper from 2022, a different set of researchers reported that three of 35 patients who visited their clinic from July 2021 to December 2021 experienced a leprosy complication or a reaction shortly after receiving a COVID-19 vaccine.
Editor’s note: This story has been updated with a comment from Dr. de Barros.
By Zachary Stieber – originally published on The Epoch Times
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news.
LINKS MAIN SOURCES